• Geyser Brands has completed its first test harvest and second harvest as a cannabis cultivator under Health Canada’s licensing regulation, and it is working to complete licensing for direct-to-consumer sales; its third harvest, now in the ground, promises a 200 percent yield increase over the first two harvests
• GYSR recently undertook a $400,000 private placement financing bid and welcomed two new investor relations officers to boost its management team
• The company has signed a non-binding letter of intent to acquire the cannabis brands and assets of Solace Management Group

Cannabis cultivator Geyser Brands Inc. (TSX.V: GYSR) is beginning to steam its way into an industry centered on what is known as a natural, healthful recourse for people struggling to manage insomnia, digestive difficulties, pain and inflammation. Geyser is building brands and celebrating the successful March harvest of its first test crops under the requirements of Health Canada’s license to cultivate.

Geyser Brands is a British Columbia-based company producing consumer health care products and brands through a formulation laboratory focused on enhancing the bio-availability and shelf stability of all-natural, hemp-derived cannabidiol (CBD) products. The company’s proprietary NanoFusion technology is at the heart of its topical, cream, beverage and baked goods, oil and tincture formulations for promoting human and pet health. Its strategy is to build and market brands nationally and internationally, establishing retail channels and direct-to-consumer experiences for its hemp-infused products and enhancing the products with CBD where legal.

Geyser began trading on the TSX Venture Exchange in December, and, with its first and second harvests under its belt (http://ibn.fm/BN5Vz), the company is working to complete a processing and sales license, which will allow GYSR to extend its products into the regulated Canadian cannabis market and direct-to-consumer medical market.

On April 18, the company announced that it is undertaking a private placement financing of up to 615,385 units at $0.65 per unit, with each unit including a common share and a purchase warrant exercisable into an additional common share at a price of $0.85 per share (http://ibn.fm/JvlLj). The placement is expected to generate gross proceeds of up to C$400,000 as a means to provide general working capital for Geyser’s growth initiatives.

“Investing in operational capacity expansion is vital to maintaining our brands’ existing leadership positions in the global cannabis industry,” CEO Andreas Thatcher stated in the announcement. “This financing gives us additional resources so we can maintain our momentum and launch ourselves through the window of opportunity that exists domestically and abroad so we can continue to lead a sector forward into new territory.”

Geyser has also augmented its executive staff, recently welcoming Doug Kerr and Alan Jones as its investor relations officers (http://ibn.fm/nEQTm). The pair brings industry experience from working with Wildflower Brands Inc. and Phivida Holdings Inc., respectively, where they helped the companies communicate their corporate strategies to shareholders.

Under the terms of joining the management team, Kerr received 250,000 stock options to purchase common shares exercisable at a price of $0.70 per share, and Jones was granted 125,000 options.

In February, Geyser signed an LOI with Solace Management Group Inc. to acquire Solace’s brands and assets, including hemp-infused pet treat brand ‘Apawthecary Pets’, hemp-based product line ‘Apothecary Naturals’, hemp-based tattoo after-care products ‘Apothecary Ink’, hemp-infused freeze-dried pet products for dogs and cats ‘WildTail Pets’, and the company’s research and development arm, Apothecary Labs.

Solace already distributes its products in Canada through over 3,000 stores, with international distribution to European, Caribbean and North American markets.

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at http://ibn.fm/GYSR

• Marijuana Company of America Inc. has returned to its roots with a joint venture to launch a cannabis delivery service targeted at California’s recreational market
• Market researchers predict that California’s cannabis sales will hit $5.1 billion this year and $7.7 billion by 2022
• MCOA’s year-end financial report noted an increase of 840 percent in annual revenues, thanks primarily to the company’s proprietary hempSMART brand

Marijuana Company of America Inc. (OTCQB: MCOA) is solidifying its position as an innovative pioneer in the cannabis industry as it forms a strategy for new growth and celebrates significant revenue gains over the past year.

Marijuana Company of America has long developed a presence in the hemp-derived product market, edifying a framework of cannabidiol (CBD) cultivation and distribution opportunities primarily through its proprietary hempSMART brand. However, as legislative and industry opportunities open up, MCOA is re-establishing its root identity as the Marijuana Company of America, as exemplified by its recent acquisition of a 20 percent interest in a licensed manufacturer, distributor and retail delivery service for volatile cannabis products in California (http://ibn.fm/wphq0).

“We have aspirations of becoming a major distributor, delivery service and manufacture in California,” MCOA CEO Don Steinberg stated in announcing the agreement with Natural Plant Extract of California (“NPE”).

Together, the companies aim to form a premier cannabis delivery company named ‘Viva Buds’, which will serve as the marketing arm for the new retail cannabis delivery service launched by NPE subsidiary Northern Lights Distribution in California. The joint venture is expected to begin with Los Angeles-area distribution before extending to other parts of the state.

A year into California’s legalization of recreational marijuana use, more than half of the municipalities in the state still did not have laws governing the industry entering 2019 (http://ibn.fm/i6dD0), and regulatory differences between the state’s varied municipalities have stymied efforts to legally deliver cannabis products to some areas, although a contested court ruling in January opened the way for companies to bypass local limitations (http://ibn.fm/XZqQu).

Analysts with plant industry advisory firm Cannabis Business Plan predict that California’s cannabis market will reach yearly revenues of $7.7 billion by 2022, with 61.5 percent of the overall market driven by recreational-use marijuana (http://ibn.fm/MrfhL), while BDS Analytics researchers forecast California cannabis sales of $5.1 billion this year  (http://ibn.fm/vhPAA).

The Viva Buds rollout follows on the heels of MCOA’s financial successes in 2018. The company recorded an 840 percent year-over-year increase in total revenues, rising from $26,830 to $252,135 (http://ibn.fm/Cahq7). Its gross profit for 2018 increased from a 47 percent gross margin to a 68 percent gross margin, while the company’s net loss from operations decreased by 82 percent from the prior year.

“Our financial results were better than many other cannabis public companies in our sector, which are still in the development stage and not yet producing revenue,” CFO Jesus Quintero stated in the news release. “Marijuana Company of America, through our hempSMART brand, has experienced a dramatic increase in sales, most of which occurred in fourth quarter. This trend is continuing to grow in first and second quarter of 2019. We think our shareholders are going to be very satisfied with the execution of our highly aggressive growth and restructuring plans in 2019.”

CEO Don Steinberg added that the company expects to complete the acquisition of a California marijuana manufacturing and distribution license shortly, which could allow Marijuana Company of America to capture additional market share.

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• The second and final tranche of a Black Iron private placement will contribute to gross proceeds exceeding $1.59 million; these funds are expected to be used for Shymanivske iron ore project advancement
• Black Iron needs the financial resources to secure essential land surface rights and to further discussions surrounding project construction financing
• The company also announced discussions with the Ukrainian Ministry of Defense regarding the transfer of a parcel of land to be used for the construction of its processing plant and waste rock storage facility

Toronto-based Black Iron Inc. (TSX: BKI) (OTC: BKIRF) (GR: BIN) recently closed the second and final tranche of an earlier announced private placement of units. The funds generated through the non-brokered private placement are earmarked for securing essential land surface rights and furthering the advancement of Shymanivske iron ore project construction and financing.

Pursuant to the closing of the second tranche, the company issued 9,043,950 units at a price of $0.06 per unit for gross proceeds of $542,637. Combined with the closing of the first tranche, the private placement is set to generate gross proceeds of $1,593,143.

The current Black Iron focus is on advancing the development of its wholly owned Shymanivske iron ore project in Krivyi Rih, Ukraine, toward construction. The mining-friendly area is surrounded by five other operating iron ore mines in very close proximity to all of the infrastructure necessary to allow for a low upfront cost phased build, including railway, power, port and skilled labor.

At the end of March 2019, Black Iron announced that Ukraine’s government had agreed to develop a plan to transfer a key parcel of land to the company. The company requires additional land suitable for the placement of its processing plant, tailings and waste rock. The transfer is expected to be completed after additional discussions focusing on a compensation package that will cover the replacement and relocation of Ministry of Defense facilities, as well as repatriation of some surrounding land.

The parcel of land is suitable from both social and environmental standpoints, Black Iron announced in a news release (http://ibn.fm/4Skwl). Its close proximity to Shymanivske also makes it a cost-efficient choice that should reduce the expenses linked to hauling ore and waste.

As per the announcement, Black Iron plans to build its Shymanivske iron ore project in two phases. The company will make use of the solid fundamentals that the area has to offer, which include the excellent infrastructure, skilled local labor and close proximity to steel mills located in Turkey, Europe and the Middle East.

The Shymanivske iron ore project is expected to produce an ultra-high grade, 68 percent iron ore concentrate. The operating cost is forecast to be low, at roughly $31 per ton, with a capital intensity of less than $95 per ton of capacity.

Black Iron intends to produce high-grade pellet feed, as the concentrate available at Shymanivske is an ideal source for pellets, because it doesn’t have to be ground finer. The price of high-grade pellet feed is anticipated to grow disproportionately on the iron ore market. Since November 2018, iron ore prices have gone up nearly 40 percent and are currently at their highest levels in almost a year.

The technical and scientific contents of this article have been reviewed and approved by Matt Simpson, P.Eng., CEO of Black Iron, who is a Qualified Person as defined by NI 43-101.

For more information, visit the company’s website at www.BlackIron.com

NOTE TO INVESTORS: The latest news and updates relating to BKIRF are available in the company’s newsroom at http://ibn.fm/BKIRF

• Proprietary genetics program with strains high in CBG, CBD, CBN and other high-potential cannabinoids
• Exclusive rights to 1 million rare CBG seeds for the 2019 growing season and beyond
• Biomass producing higher yields with up to 20% full-spectrum CBD and other cannabinoids
• Multistate farming presence in Oregon, California, Colorado and Kentucky projected to cultivate 3,000 acres by 2020
• Sales and distribution channels include contract wholesale, bulk wholesale, in-house brands and white labeled products
• Disruptive product formulation ensures water solubility, high bioavailability and efficacy
• S. hemp-derived CBD sales forecast calls for $22 billion by 2022

Hemptown USA, headquartered in Central Point, Oregon, is a proven grower of full-spectrum hemp biomass grown using premium seed genetics that contain less than 0.3% THC and exceptionally high cannabinoid (CBD) content of up to 20%. The company’s “soil to oil” methodology combines seasoned professionals working in hand-picked agricultural microclimates located in Oregon’s famed Emerald Triangle, Kentucky and Colorado.

Hemptown has exclusive rights to 1 million rare CBG (cannabigerol) seeds genetically programmed to yield from 15% to 20% full-spectrum non-intoxicating cannabinoids. As a result of a long-standing relationship with the one of the world’s most respected cannabis breeding companies – Oregon CBD Seeds – Hemptown is positioned to be a leading CBG producer in the U.S. in 2019 and beyond.

In 2018 Hemptown’s harvest from its Oregon hemp farm was 150,000 pounds of full-spectrum biomass with CBD content hovering around 17%. 2018 harvest revenue expected to range from $8.1 million to $12.6 million. The company is scaling up operations in 2019 to meet market demands and projects it will reap over 1,000,000 pounds. By 2020, Hemptown projects potential revenues in the $100 million to $200 million range are possible once additional farming operations are at full strength.

Growth Strategy

By 2020, Hemptown anticipates it will have more than 3,000 acres in several states dedicated to hemp farming. Expansion plans include increasing in-house extraction capabilities to boost profit margins by providing additional CBD and CBG isolates and distillation services. Development of business-to-business channels as well as new products and formulations for the direct-to-consumer market, along with several strategic acquisitions, are also key to Hemptown’s growth strategy.

Hemptown plans to expand distribution and growing operations globally through strategic partnerships and development of contracts with leading Fortune 500 brands in European markets. The company intends to grow its IP portfolio by developing a proprietary water-soluble cannabinoid delivery system. Not to be confused with water-compatibility, water-soluble cannabinoids combine seamlessly with other liquids, have a superior shelf life, and deliver dramatically increased efficacy to the consumer.

Branded Products

Hemptown’s first in-house branded product line combines the inspiring strength found in the unbridled nature that surrounds the company’s original hemp farm in the Siskiyou Klamath region of Oregon. Siskū is set to redefine the cannabinoid packaged goods space with an elegant look, clean feel and potent, reliable efficacy.

Custom product lines can also be created for any product manufacturer as Hemptown brings GMP and ISO accredited processing facilities online in 2019. Together with Oregon CBD Seeds and Hemptown’s product sciences team, Hemptown will be able to create custom, proprietary full-spectrum CBD and CBG oils and pure isolates.

Management Team

Company Chairman Rod Wolterman founded Hemptown’s Oregon operations in 2016. He has extensive experience in the cannabis sector having been active within the space since 1998. Wolterman has also acted as a private equity investor in numerous medical marijuana dispensaries and cultivation operations in southern California.

CEO John Cummings has over 20 years of experience in finance, marketing, sales and project management. He led the compliance and special projects efforts for Kings Garden, one of the largest vertically integrated operators in California. Cummings also spent a year in Europe launching the continent’s first GMP and ISO-accredited cultivation and manufacturing facility.

Dr. Gordon Chiu is chief science officer for Hemptown USA. He has more than 15 years of combined domestic and international experience in biomedical, chemical, cosmetic, medical and technology industries. A graduate of Rensselaer Polytechnic Institute with a master’s degree from Seton Hall University, Chiu is leading Hemptown’s cannabinoid research team and is responsible for filing IP patents, specifically in the areas of water-solubility, bioavailability and peptide sequencing.

For more information, visit the company’s website at www.HemptownUSA.com

• Sugarmade is focusing its hydroponic agricultural supplies operation on the emerging hemp industry
• Passage of the 2018 Farm Bill opened the gates to a new wave of hemp farming that portends a possible boom market
• The hemp industry has suffered from the same banking antipathy afflicting state-legal marijuana businesses because of federal regulation of cannabis’ drug uses
• Congress has begun considering legislation that would potentially bar federal agencies from penalizing financial institutions that serve cannabis-related businesses

Congressional legislation that aims to open banking institutions’ doors to the cannabis industry would not only benefit state-legal marijuana businesses, but also agricultural businesses working with cannabis’ non-drug hemp plant strains, such as hydroponic equipment supplier Sugarmade Inc. (OTCQB: SGMD).

Separate bills introduced in both the House and the Senate are attempting to address public safety concerns that have arisen as 10 U.S. states have moved to legalize recreational marijuana use and as medical cannabis use has been legalized in two-thirds of states. Because recreational and medicinal cannabis drugs continue to be classified as controlled substances by the federal government’s criminal enforcement divisions, regardless of the states’ rights groundswell, bank institutions insured by the federal government have been unwilling to risk depositor insecurity by doing business with federally illegal enterprises.

The lack of banking services has led the cannabis enterprises to transact finances, including corporate taxes, in sometimes large sums of cash that can’t be legally mailed and have to be carried to their destinations, creating fears of heightened criminal vulnerability as the cash is moved. However, the new Congressional measures would “block federal agencies from being able to “prohibit, penalize, or otherwise discourage a depository institution from providing financial services to a cannabis-related legitimate business or service provider or to a State, political subdivision of a State, or Indian Tribe that exercises jurisdiction over cannabis-related legitimate businesses,” if the bills are approved (http://ibn.fm/ynznc).

Such a law would allow growers to establish secured lines of credit, use electronic cards and become better business partners – all without having to worry about safeguarding cash transfers with every company with which they do business.

Sugarmade, headquartered in Los Angeles County, has various business operations in diverse marketplaces, including packaging and paper goods for various industries and agricultural supplies. The company is one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space to serve the burgeoning sector as farms have been emboldened by the passage of last year’s Farm Bill, which restored hemp to agricultural oversight, free of Drug Enforcement Agency prohibitions (http://ibn.fm/sW6DW).

Sugarmade recently inked an agreement with Kentucky-based hemp cultivator Hempistry Inc. to deliver resources for its plant micropropagation work – a process that involves cloning or “propagating” new hemp plants from existing “mother” plants that have shown a desirable genetic profile (http://ibn.fm/xzt4f). A large portion of the minimalist hemp industry that exists in North America uses the propagation process instead of growing crops from seed, and the micropropagation process offers the additional advantage of producing a very large number of plants simultaneously, according to the company.

According to Kentucky Commissioner of Agriculture Ryan Quarles, the number of the state’s applications to farm hemp is expected to increase by about five times between 2018 and 2019 (http://ibn.fm/fRDOy). Hemp acreage is expected to soar from 16,000 acres last year to more than 50,000 acres this year, and Sugarmade is well positioned to provide many of the supplies for successful micropropagation operations as demand grows. The company has already begun processing micropropagation supply orders.

For more information, visit the company’s website at www.Sugarmade.com

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SUGAR

• Nightfood ice cream is now available at Lowes Foods locations in North Carolina, South Carolina and Virginia
• The next run of Nightfood ice cream will include the 2019 ‘Product of the Year’ logo in order to drive consumer trial at retail
• NGTF’s CEO will aim to raise the company’s global profile when he speaks at the 13th Annual Global Dairy Congress in Portugal

Nightfood Holdings Inc. (OTCQB: NGTF), owner of Nightfood ice cream, recently added distribution to all 78 Lowes Foods supermarkets in North Carolina, South Carolina and Virginia as part of its expansion program (http://ibn.fm/udGWm). The company is working toward a national rollout, with a goal of selling into 10,000 retail doors by March 31, 2020. Should it be successful in hitting those distribution goals, Nightfood’s revenues could approach or exceed $10 million per quarter by mid-2020 (http://ibn.fm/efmhV).

Tarrytown, New York-based Nightfood Holdings Inc. owns Nightfood Inc. and its wholly owned subsidiary, MJ Munchies Inc., which was formed in 2018. The company is focused on the estimated 80 percent of at-home ice cream consumption that occurs before consumers head to bed. Nightfood ice cream is specifically formulated by sleep and nutrition experts for nighttime snacking, pioneering a category of foods to be known as ‘sleep-friendly’.

“As we gear up for the supermarket category review season, which begins in a few months, Lowes was one of the key accounts we focused on for the early part of the year,” Jim Christensen, Nightfood’s VP of ice cream sales, stated in a news release.

Globally, NGTF has started the process of registering the Nightfood mark for its ice cream brand in strategic international territories (http://ibn.fm/BeOPg).

NGTF CEO Sean Folkson believes that “overseas expansion is in our future.” The company is engaged in ongoing talks with potential international trade partners, according to Folkson, although there is currently no firm timetable for overseas expansion.

NGTF is raising its profile internationally. Folkson will speak in late June at the 13th Annual Global Dairy Congress in Lisbon, Portugal. The annual event is organized by Zenith Global, a UK-based food and drink consultant. The event regularly draws attendees from food giants such as PepsiCo, Mondelez International, Chobani and others (http://ibn.fm/sS5Dl).

Nightfood ice cream recently won the ‘Product of the Year’ award in the ice cream category in a Kantar survey of more than 40,000 consumers. The company also announced plans to market a brand called ‘Half-Baked’ in the CBD and marijuana edibles space.

For more information, visit the company’s website at www.Nightfood.com

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

• Sproutly Canada is committed to redefining the cannabis industry
• SRUTF’s ACMPR-licensed facility was built for the cultivation of pharmaceutical-grade cannabis
• The company is developing the Aqueous Phytorecovery Process

Based in Vancouver, British Columbia, Sproutly Canada Inc. (OTCQB: SRUTF) (CSE: SPR) (FRA: 38G) engages in developing and bringing to market consumer cannabis products, with an emphasis on beverages. The company’s primary mission is to become the foremost supplier of water-soluble cannabis solutions and bio-natural oils to the developing beverage and consumables market. Sproutly Canada’s ACMPR-licensed facility in Toronto, Ontario, was built to cultivate pharmaceutical-grade cannabis.

Fundamentally, Sproutly is combining advanced cannabis cultivation and transformational technologies to redefine the cannabis industry. Via its acquisition of Infusion Biosciences, the company is bringing to market a patent-pending technology called the Aqueous Phytorecovery Process (APP) (http://ibn.fm/8YiAP). Sproutly is the exclusive licensee of Infusion’s APP technology for the recovery of naturally water-soluble phytochemicals (Infuz2O). Sproutly also owns exclusive rights to the technology in Canada, Australia, Jamaica, Israel and the European Union.

True natural-water solubility replaces traditional water-compatible solutions, improving the body’s ability to use cannabinoids. APP provides onset and offset times that mirror the same effect as inhaled marijuana. This process maintains stability without modifying cannabis compounds. APP technology is a highly scalable and low-cost recovery method. It yields desirable economics versus other extraction methods, which necessitate additional processing beyond extraction to produce consumable products (http://ibn.fm/eaL0q).

Consumers are moving toward greater acceptance of cannabis. However, the trend is away from smoking the plant in favor of the consumption of cannabis products as drinks and oils. The National Post noted in a recent release (http://ibn.fm/dQqw9) that “in a second wave of recreational legalization, cannabis-infused food and drink will be lawful in Canada no later than October 17, 2019, and sales are projected to boom.” The potential Canadian cannabis beverage market is estimated to reach $4.4 billion by 2024, with the total Canadian cannabis market projected to top $8.7 billion that same year (http://ibn.fm/RSwdv).

Sproutly Canada is positioned to leverage this trend. The company’s plan is to capitalize on domestic and worldwide opportunities by executing on partnerships with local and internationally established consumer brands. The goal is to take advantage of the existing customer bases of these brands. In addition, the company will concentrate on expanding brand loyalty and assisting with marketing while supporting distribution networks.

In addition to Infusion Biosciences Inc., Sproutly Canada’s current brands include Toronto Herbal Remedies (“THR”). Under ACMPR, THR is a licensed producer. A biotechnology company, Infusion Biosciences focuses on discovering and commercializing unique, science-based cannabis technologies.

Recently, Sproutly Canada announced that THR was granted a processing license from Health Canada. This license permits THR to produce cannabis oil and related products (http://ibn.fm/IZ4Mp). Moreover, the license permits the company to conduct certain research and development activities, including the formulation of proprietary beverage products.

In a news release, Sproutly Canada CEO and Director Keith Dolo stated, “We are making steady progress towards achieving Sproutly’s mission of delivering a safe and consistent whole-plant experience from cannabis, with a lead position in the beverage market. The Processing License grant is a major milestone towards the path to commercializing our cannabis beverages and other edible products.”

With a production facility capable of producing up to 1,400 kilograms per year, Sproutly Canada is positioned to benefit from the trend toward cannabis drinks and oils. Sproutly remains centered on its mission of pursuing and developing innovative technologies for the production, processing and delivery of cannabis.

For more information, visit the company’s website at www.Sproutly.ca

NOTE TO INVESTORS: The latest news and updates relating to SRUTF are available in the company’s newsroom at http://ibn.fm/SRUTF

• Medical and recreational cannabis is legal for adult-use in Canada with consumables expected to be available in October 2019
• Passage of 2018 Farm Bill in the U.S. opens hemp production nationwide
• Legal cannabis sales worldwide reached $12 billion in 2018 with analysts projecting up to $32 billion in sales by 2022
• CBD-infused consumables are expected to gain popularity with edibles growing to be a $4 billion market in the U.S. and Canada by 2022
• Nanofusion technology overcomes insolubility problems associated with CBD oils, improving bioavailability and providing for controlled onset and offset times

Geyser Brands Inc. (TSX.V: GYSR) is a consumer healthcare company that builds and markets some of the world’s most loved cannabis products and brands in the nutraceutical, cosmetics, food and beverage and pet sectors. Using its proprietary nanotechnology formulation, the company delivers creams, beverages, baked goods and tincture formulations with superior bioavailability and water solubility.

NanoFusion Technology

The efficacy of most hemp products is restricted as the insoluble nature of the molecules prevents most of the product from permeating the skin or entering the body system. Geyser Brands solves this insolubility problem with an advanced delivery system that quickly and efficiently transports therapeutic agents directly to the bloodstream for maximum absorbency.

Made with all-natural materials, NanoFusion technology offers an array of advantages: enhances penetration for deeper skin penetration; improves the transport of active ingredients for site-specific targeting; delivers active ingredients across cell membranes for release within the cell; provides longer shelf-life and stability of molecules.

Operations

Geyser Brands operates a 7,000-square-foot facility in Port Coquitlam, British Columbia, where its initial cannabis cultivation generated the first revenues out of the company’s cultivation license granted in October 2018. Geyser Brands is approved as a licensed producer in compliance with Health Canada standards, which allows the company to pursue its processing and sales license. Obtaining this license will enable the company to extend its products and brands into the regulated Canadian cannabis market and directly to the consumer medical market.

Geyser Brands’s integrated production chain and formulation lab develops innovative products using high-quality hemp and CBD for healthy lifestyle brands while its R&D lab produces product formulations designed to enhance bio-availability of hemp and CBD and shelf stability while maintaining all-natural ingredients and ensuring premium quality.

Geyser Brands will continue to seek opportunities to invest into the research and development of unique high-quality proprietary strains and technologies that target specific health-related conditions such as pain and inflammation reduction, insomnia, digestive issues and other commonly known ailments.

Growing Portfolio

Among the brand formulations in Geyser Brand’s portfolio are:

• Apothecary all-natural Hemp Terpene Pain Cream with optimal skin permeation
• Prohibition Cold Brew Mocha designed with water soluble hemp molecules
• Apothecary health products created to deliver fast-acting and high bioavailability in a spray formulation
• Baked hemp infused pet products, designed to alleviate anxiety and pain, created with NanoFusion for dosage control

Management Team

Since 2014, Geyser Brands’ CEO and Co-Founder Andreas Thatcher has been a principal at Rhizome Group, an entertainment company focused on building media IP through creative and market development. He previously was a founding partner at Rhizome Capital LLC, a U.S.-based media investment company specializing in marketing and distribution financing, and worked in the Investment Banking industry in London and Toronto. Thatcher holds a master’s degree in economics.

CFO Barry McKnight obtained his bachelor’s degree from the University of British Columbia and is a Chartered Professional Accountant and Certified Management Accountant registered in British Columbia. McKnight has over 20 years of experience as the principal of Barry D. McKnight Inc. He formerly was also a director of Indigo Sky Capital Corp. and has been the CFO and a director of the Company since 2016 and Corporate Secretary of the Company since 2017.

Geyser Brands’s Co-Founder Brad Kersch brings a strong business background with over 20 years of experience in successful startups and working with Fortune 500 companies. He spent his early years in the advertising and marketing field and went on to form Hyperware, a clothing company that sold branded clothing to retailers across Canada before selling to clothing giant Ocean Pacific (OP). Kersch became the president of Shoreline Studios, Canada’s largest and oldest studio for film and TV. In 2014 he started Solace Management Group, a hemp product company focused on pet, cosmeceutical, and nutraceutical markets. As of February 2019, Geyser Brands signed a non-binding LOI to acquire Solace Management. Upon completing the proposed Solace acquisition, Geyser Brands intends to launch into the execution phase of its plan — to take its brands global through retail and digital direct-to-consumer experiences, launching its hemp-infused cannabis brands and products in the U.S., European Union, and Asia, and its CBD-infused line of products in jurisdictions where the therapeutic ingredient is legal.

Kuldip Gill, head of Geyser Brands’ R&D program, has more than 35 years of experience in the cannabis industry. Gill built the largest manufacturing facility in the lower mainland in Surrey, British Columbia, complete with R&D, analytical and quality control labs approved by both the FDA and Health Canada. He has to date created over 3,500 formulas, most notably Lakota pain relief gel. Gill’s experience and proven track record is evident in the strongly marketable formulations he has developed and sold worldwide.

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at http://cnw.fm/GYSR

• Even with its cultivation facility only 20 percent operational, the company reported record revenues from its first cannabis sales in 2018
• Flowr announced that 20 fully constructed grow rooms will be available in Q3 2019, increasing its annual production capacity to 10,000 kilograms
• The company has also announced plans to expand its product line with the sale of seeds and clones once production is ramped up

The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF) registered a number of important milestones in 2018, despite the fact that its world-class cultivation facility was only 20 percent operational at the time. In an official conference call held on April 4, 2019, the company announced its first revenues on sales of premium cannabis in 2018. Flowr Corporation sold nearly 405 kilograms of cannabis produced at the grow rooms of its Kelowna 1 facility (http://ibn.fm/dhhdF).

Gross revenue reached C$3.3 million and net revenue was established at C$2.9 million. The average net realized price was C$7.08 per gram, after Flowr received its sales license in August 2018.

The Flowr cultivation facilities feature proprietary, patent-pending systems designed to consistently generate high crop yields. The 84,000-square-foot flagship Kelowna 1 facility is located on a seven-acre property in Kelowna, British Columbia. The facility is engineered to meet pharmaceutical industry production standards for cleanliness.

Currently, 10 of the Kelowna 1 grow rooms are licensed for use. Eight rooms are propagated with plants, and, by the end of the third quarter of 2019, Flowr anticipates having 20 fully-constructed grow rooms. Once that milestone is reached, Flowr Corporation’s cultivation capacity is expected to ramp up to 10,000 kilograms of premium cannabis annually.

According to Flowr Co-CEO Vinay Tolia, the revenue numbers are indicative of the company’s ability to grow and process a high-quality product, even while only a fraction of the world-class Kelowna facility is operational.

On top of completing the facility by the third quarter of 2019, Flowr also aims to expand its product line, as an official company announcement detailed (http://ibn.fm/MdriE). Flowr expects to start selling a selection of its premium high-quality cannabis in clone and seed form to both national and international customers.

“As we ramp up production, we believe Flowr will be able to offer the select cultivars we use to produce our premium cannabis to cultivators globally,” company Co-CEO Tom Flow announced in a news release.

Mid-March 2019, Flowr Corporation also announced the launch of its medical cannabis products for sale via the online Shoppers Drug Mart platform (http://ibn.fm/egTA2). Flowr Corporation and Shoppers Drug Mart confirmed a sales agreement at the beginning of 2019. The collaboration will simplify the delivery of premium medical cannabis products throughout Canada.

To order Flowr products online, patients need to submit a completed medical document from their health care providers. Shoppers Drug Mart advisors will next contact the health care practitioner for verification purposes before products get shipped.

Previously, Flowr products were available online via the company’s web portal. As per the new agreement, Shoppers Drug Mart is now the exclusive direct-to-patient Flowr product distributor.

For more information, visit the company’s website at www.Flowr.ca

NOTE TO INVESTORS: The latest news and updates relating to FLPWF are available in the company’s newsroom at http://ibn.fm/FLWPF

• The company’s acquisitions include fully-integrated licensed medical marijuana businesses and a cultivation/processing center in Arizona
• Investments have been announced for strategically located properties in Michigan with 10 approved cultivation licenses and one processing license
• An overwhelming 92 percent of states in the U.S. have legalized some form of cannabis
• The global legal marijuana market is expected to exceed $146 billion by the end of 2025

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 7IP), also known as Innovative Properties Inc., is a Canadian company focused on strategically investing in high quality cash-flow assets within the cannabis sector. These carefully selected investments are primarily located in U.S. states that have legalized some form of cannabis, from medicinal to recreational adult-use and cannabidiol (CBD) products (www.NabisHoldings.com).

The company features a strong management team, led by two of the industry’s leading operators, that is working to establish an ‘Anchor Investment Portfolio’ of high-quality assets, strategically selected over a short period of time and at the right price. Nabis Holdings specifically seeks out U.S. cannabis assets and brands now doing business in limited license states. The company’s focus on strategic revenue generation, EBITDA and growth is enshrined in its motto: ‘One team. One goal.’ Similarly, this focus is reflected in the company’s name: ‘Na bis’, which is defined as ‘repeat performance’ or ‘encore’.

To date, Nabis Holdings has announced investments capable of creating immediate value in multiple vertical cannabis businesses located in some of the nation’s largest medical marijuana markets, including Arizona, Michigan and Washington state (http://nnw.fm/GC6Mx). Nabis has also invested in Hivemind Refinery, a premium consumer CBD brand; and Bloombox, a leading intelligent retail and supply chain cannabis software platform.

Management’s hands-on approach to identifying proven operators with strong brand traction; pharma-grade cultivation, extraction and dispensaries; and other operations is quickly expanding the company’s ‘Anchor Investment Portfolio’. The company is also exploring investment opportunities in Israel, the European Union and other nations.

The global legal marijuana market is expected to reach $146.4 billion by the end of 2025, according to a Grand View Research Inc. report. Increasing medical research into utilizing cannabis or CBD to treat forms of cancer, epilepsy, mental disorders, chronic pain and other diseases is expected to propel market growth, as the report states (http://nnw.fm/B1bgw).

Nabis CEO Shay Shnet and President Mark Krytiuk have been directly involved in the cannabis industry and financial sectors for decades and were most recently founding partners of MPX Bioceutical. MPX was the subject of the largest public takeover in the U.S. cannabis industry to date, as it merged with iAnthus for C$835 million. Nabis Holdings seeks to be a leading investor with a portfolio of vertically integrated, multistate cannabis operations across the U.S. and beyond.

For more information, visit the company’s website at www.NabisHoldings.com